PALO ALTO, Calif.--(BUSINESS WIRE)--Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced the appointment of Dave Daly as Chief Executive Officer. With more than 30 years of cancer diagnostics and executive leadership experience, including at Thrive Earlier Detection (acquired by Exact Science ‘EXAS’) and Foundation Medicine (acquired by Roche), Daly is ideally positioned to spearhead Exai’s accelerated product development and partnering strategy.
Exai’s liquid biopsy platform uses RNA sequencing to identify a novel category of cancer-associated, small non-coding RNAs, termed orphan non-coding RNAs (oncRNAs). oncRNAs are actively secreted from living cancer cells and are abundant in the blood. When combined with proprietary artificial intelligence, oncRNAs have multiple advantages over tests that utilize circulating tumor DNA, including superior sensitivity and specificity, low cost of goods, as well as the ability to reveal dynamic changes in the biology of a patient’s tumor over time.
“Since its founding, Exai has amassed the largest oncRNA dataset and honed its proprietary generative AI models to deliver unprecedented sensitivity across the major cancer types,” stated Michael Pellini, General Partner at Section 32 and Board member of Exai Bio. “As the company accelerates product development of its novel platform, we are thrilled to welcome Dave Daly, who has the deep diagnostics expertise and leadership qualities to lead the next chapter of Exai.”
Most recently, Daly was President and Chief Operating Officer at Singular Genomics. Prior to this role, Daly served as CEO at Thrive Earlier Detection, a liquid biopsy company focused on multi-cancer early detection that was acquired by Exact Sciences Corporation. During his extensive career in diagnostics, Daly has also served in key leadership roles at Illumina where he was Senior Vice President and General Manager of Commercial Operations for the Americas Region, Foundation Medicine where he was Chief Commercial Officer, Life Technologies where he led the oncology business unit, and Clarient where he served as Chief Commercial Officer.
“Decades spent in the diagnostics industry allowed me to clearly see that Exai’s novel liquid biopsy platform stands out as one that can be both truly high performing and accessible for a broad array of patients,” stated Dave Daly, Chief Executive Officer of Exai Bio. “I look forward to leading the team as we build our tests and establish key partnerships that will unlock the platform’s full potential for cancer care.”
About Exai Bio
Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary oncRNA- and AI-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. For more information, please visit us on www.exai.bio and follow us on Twitter and LinkedIn.
